Erratum: Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein e knock-out mice (International Journal of Cardiology (2010) 139 (113-22) DOI: 10.1016/j.ijcard.2008.10.013);Molecular mechanisms of irbesartan suppressing atherosclerosis in high cholesterol-diet apolipoprotein E knock-out mice

International Journal of Cardiology

Volumn 139, Issue 2, 2010, Pages 113-122

  Yao, Rui ^a   Cheng, Xiang ^a   Chen, Yong ^a   Xie, Jiang Jiao ^a   Yu, Xian ^a   Liao, Meng Yang ^a   Ding, Ying Jun ^a   Tang, Ting Ting ^a   Liao, Yu Hua ^a  

^a Union Hospital of Huazhong University   (China)

Author keywords

Angiotensin type 1 receptor blocker; Atherosclerosis; Hypercholesterolemia; Inflammation; Oxidative stress

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APOLIPOPROTEIN E; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; IRBESARTAN; JANUS KINASE 2; LIPID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE;

EID: 77549085922     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.08.120     Document Type: Erratum

References (49)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Ferrario C.M., and Strawn W.B. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98 (2006) 121-128
3. Kim S., and Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52 (2000) 11-34
4. Das UN. Is angiotensin-II an endogenous pro-inflammatory molecule?. Med Sci Monit 11 (2005) RA155-RA162
5. Mehta P.K., and Griendling K.K. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 292 (2007) C82-C97
6. 1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 112 (2007) 417-428
7. Dandona P., Dhindsa S., Ghanim H., and Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens 21 (2007) 20-27
8. Cheng Z.J., Vapaatalo H., and Mervaala E. Angiotensin II and vascular inflammation. Med Sci Monit 11 (2005) RA194-RA205
9. Strawn W.B., Chappell M.C., Dean R.H., et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 101 (2000) 1586-1593
10. Suzuki J., Iwai M., Mogi M., et al. Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation. Arterioscler Thromb Vasc Biol 26 (2006) 917-921
11. Miyazaki M., and Takai S. Anti-atherosclerotic efficacy of olmesartan. J Hum Hypertens 16 Suppl 2 (2002) S7-S12
12. Iwai M., Inaba S., Tomono Y., et al. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. Hypertens Res 31 (2008) 161-168
13. Morawietz H., Erbs S., Holtz J., et al. Endothelial protection, AT1 blockade and cholesterol-dependent oxidative stress: the EPAS trial. Circulation 114 (2006) I296-I301
14. Khan B.V., Navalkar S., Khan Q.A., et al. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease. J Am Coll Cardiol 38 (2001) 1662-1667
15. Navalkar S., Parthasarathy S., Santanam N., et al. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 37 (2001) 440-444
16. Iwai M., Chen R., Li Z., et al. Deletion of angiotensin II type 2 receptor exaggerated atherosclerosis in apolipoprotein E-null mice. Circulation 112 (2005) 1636-1643
17. Inoue S., Egashira K., Ni W., et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation 106 (2002) 2700-2706
18. Paigen B., Morrow A., Holmes P.A., Mitchell D., and Williams R.A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68 (1987) 231-240
19. Ni W., Egashira K., Kitamoto S., et al. New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103 (2001) 2096-2101
20. Tsai S.H., Liang Y.C., Lin-Shiau S.Y., and Lin J.K. Suppression of TNF-alpha-mediated NFkappaB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells. J Cell Biochem 74 (1999) 606-615
21. Bea F., Kreuzer J., Preusch M., et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioslcer Thromb Vasc Biol 26 (2006) 2787-2792
22. Seshiah P.N., Weber D.S., Rocic P., Valppu L., Taniyama Y., and Griendling K.K. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91 (2002) 406-413
23. Schubert S.Y., Neeman I., and Resnick N. A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J 16 (2002) 1931-1933
24. Chen Y., Arrigo A.P., and Currie R.W. Heat shock treatment suppresses angiotensin II-induced activation of NF-kappaB pathway and heart inflammation: a role for IKK depletion by heat shock?. Am J Physiol Heart Circ Physiol 287 (2004) H1104-H1114
25. Fries R., and Bohm M. From risk factors to symptomatic coronary artery disease. Update cardiology 2001/2002-part I. Med Klin (Munich) 98 (2003) 218-225
26. Elisaf M. The treatment of coronary heart disease: an update. Part 1: an overview of the risk factors for cardiovascular disease. Curr Med Res Opin 17 (2001) 18-26
27. Daugherty A., Rateri D.L., Lu H., Inagami T., and Cassis L.A. Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110 (2004) 3849-3857
28. Nickenig G., and Harrison D.G. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: part II: AT(1) receptor regulation. Circulation 105 (2002) 530-536
29. Pfeffer M.A., McMurray J.J., and Velazquez E.J. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
30. Dahlof B., Devereux R.B., and Kjeldsen S.E. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
31. Pfeffer M.A., Swedberg K., and Granger C.B. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 362 (2003) 759-766
32. Tsuda M., Iwai M., Li J.M., et al. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 45 (2005) 545-551
33. Li Z., Iwai M., Wu L., et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 44 (2004) 758-763
34. Chen H., Li D., Sawamura T., et al. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun 276 (2000) 1100-1104
35. Ushio-Fukai M., and Alexander R.W. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol Cell Biochem 264 (2004) 85-97
36. Griendling K.K., Sorescu D., and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86 (2000) 494-501
37. Landmesser U., Cai H., Dikalov S., et al. Role of p47(phox) in vascular oxidative stress and hypertension caused by angiotensin II. Hypertension 40 (2002) 511-515
38. Warnholtz A., Nickenig G., Schulz E., et al. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
39. Won S.M., Park Y.H., Kim H.J., Park K.M., and Lee W.J. Catechins inhibit angiotensin II-induced vascular smooth muscle cell proliferation via mitogen-activated protein kinase pathway. Exp Mol Med 38 (2006) 525-534
40. Chen X.L., Tummala P.E., Olbrych M.T., Alexander R.W., and Medford R.M. Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ Res 83 (1998) 952-959
41. Schieffer B., Luchtefeld M., Braun S., Hilfiker A., Hilfiker-Kleiner D., and Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ Res 87 (2000) 1195-1201
42. Pfitzner E., Kliem S., Baus D., and Litterst C.M. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des 10 (2004) 2839-2850
43. de Winther M.P., Kanters E., Kraal G., et al. Nuclear factor kappaB signaling in atherogenesis. Arterioscler Thromb Vasc Biol 25 (2005) 904-914
44. Kutuk O., and Basaga H. Inflammation meets oxidation: NF-kappaB as a mediator of initial lesion development in atherosclerosis. Trends Mol Med 9 (2003) 549-557
45. Nam K.W., Kim J., Hong J.J., et al. Inhibition of cytokine-induced IkappaB kinase activation as a mechanism contributing to the anti-atherogenic activity of tilianin in hyperlipidemic mice. Atherosclerosis 180 (2005) 27-35
46. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., and Joving S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler Thromb Vasc Biol 24 (2004) 2137-2142
47. Schmieder R.E., Hilgers K.F., Schlaich M.P., and Schmidt B.M. Renin-angiotensin system and cardiovascular risk. Lancet 369 (2007) 1208-1219
48. Cook-Mills J.M. VCAM-1 signals during lymphocyte migration: role of reactive oxygen species. Mol Immunol 39 (2002) 499-508
49. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150